Compare INNV & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INNV | ENTA |
|---|---|---|
| Founded | 2007 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 485.4M | 407.5M |
| IPO Year | 2021 | 2013 |
| Metric | INNV | ENTA |
|---|---|---|
| Price | $4.99 | $14.51 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $5.00 | ★ $20.40 |
| AVG Volume (30 Days) | 242.5K | ★ 288.8K |
| Earning Date | 11-04-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $884,662,000.00 | $65,324,000.00 |
| Revenue This Year | $11.18 | $0.99 |
| Revenue Next Year | $9.58 | $0.19 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 12.48 | N/A |
| 52 Week Low | $2.60 | $4.09 |
| 52 Week High | $6.26 | $15.34 |
| Indicator | INNV | ENTA |
|---|---|---|
| Relative Strength Index (RSI) | 48.23 | 72.93 |
| Support Level | $4.94 | $11.89 |
| Resistance Level | $5.21 | $14.52 |
| Average True Range (ATR) | 0.44 | 0.86 |
| MACD | -0.02 | 0.10 |
| Stochastic Oscillator | 17.42 | 95.27 |
InnovAge Holding Corp is a healthcare delivery platform by several participants focused on providing all-inclusive, capitated care to high-cost, dual-eligible seniors. Its patient-centered care delivery approach improves the quality of care while keeping them in their homes and reducing over-utilization of high-cost care settings such as hospitals and nursing homes. The company's segment includes PACE and others. It generates maximum revenue from the PACE segment.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.